top of page


Regenerative. Therapeutic. Revolutionary.

More than one million bone grafting procedures are performed annually for debilitating pain and bone conditions, emphasizing the increasing need for efficient bone graft substitutes. Autografts are considered the “gold standard” as they provide the most successful treatment outcomes which far exceed any other products in the market. Unfortunately, the autograft harvesting procedure can lead to significant donor site morbidity including chronic pain and fracture. A safe replacement product that is as efficient as autografts can revolutionize the way we treat patients with severe bone conditions. Our bone product is currently developed as a replacement for autografts and is optimized for rapid bone repair and regeneration.

At Molecular Matrix, we believe in improving lives through innovations in science. Our technology can be used to repair damaged or missing skeletal tissues while addressing many of the limitations and side effects seen in the field.  Our hyper-crosslinked carbohydrate polymer (HCCP) technology provides a broad platform for tissue engineering in the orthopedic disciplines. HCCP has been shown to be effective for bone regeneration, evidenced by bone precursor cell activities. We believe that the advancements brought by our technology will yield superior bone regeneration products for orthopedic, spine, and trauma applications.  The following products are currently being researched:


Carriers are designed to deliver and maintain osteoinductive compounds such as bone morphogenetic proteins, tissue growth factors, bone marrow aspirates, and stem cells at their intended osseous targets. Targeted delivery improves efficacy and clinical outcomes.



Osteoconductive, resorbable scaffolds that support new bone formation while remodeling. They may be used alone or in combination with autograft to provide a bone void filler that is resorbed/remodeled and is replaced by host bone during the healing process.

bottom of page